Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Conditions

Hepatitis C

What is the purpose of this trial?

The purpose of this study is to determine if combination therapy with Pegylated Interferon Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or BMS-650032) for 24 weeks is effective and safe for treatment of Chronic Hepatitis C (CHC) compared to current standard therapy with Pegylated Interferon Alpha-2a plus RBV for 48 weeks.



Participation Guidelines

Age:
18 Years - 70 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Bristol-Myers Squibb
Dates:
March 2011
Last Updated:
September 12, 2014
Study HIC#:
1104008336

Clinicaltrials.gov ID: NCT01309932